SNPMiner Trials (Home Page)
Report for SNP rs8069645
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Effect of Polymorphisms in CD36 and STAT3 Genes on Different Dietary Interventions Among Patients With Coronary Artery Disease: a Randomized Clinical Trial With a Nutrigenetic Approach
Background: Cardiovascular diseases are the major health problem worldwide and the understanding of genetic contributions on the development of cardiovascular diseases is increasing significantly. The CD36 is a protein associated with uptake of oxidized forms of LDL and the single nucleotide polymorphism (SNP) rs1761667 A/G in the CD36 gene is correlated with increased consumption of total fat. The transcription factor STAT3 is released during the inflammatory acute phase response and the SNP rs8069645 G/A in the STAT3 gene is associated with abdominal obesity and higher intake of saturated fat. Studies have been shown the benefits of the Mediterranean diet in secondary prevention of cardiovascular disease and these dietary patterns have been often studied with nutrigenetic approach; these studies, however, are often limited to European populations, making it difficult to generalize to different populations. Hypothesis: Different dietary approaches may similarly influence in modifying metabolic, inflammatory and anthropometric profile, especially among patients with coronary arterial disease (CAD). The genetic interaction with environmental factors such as the nutrient intake, and the prescription of a different diet according to individual genotype, could influence the development and/or the treatment of cardiovascular diseases. Objective: To evaluate the effect of three dietary approaches on metabolic, inflammatory and anthropometric profile in patients with CAD and possible interactions with polymorphisms in CD36 and STAT3 genes.
NCT02202265 Coronary Artery Disease Dietary Supplement: Olive oil Dietary Supplement: Nuts Dietary Supplement: Control diet MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO:Coronary artery atherosclerosis Myocardial infarction
The transcription factor STAT3 is released during the inflammatory acute phase response and the SNP rs8069645 G/A in the STAT3 gene is associated with abdominal obesity and higher intake of saturated fat.
Primary Outcomes
Description: LDL-cholesterol, in mg/dL
Measure: LDL Time: twelve weeksSecondary Outcomes
Description: total cholesterol (TC), in mg/dL)
Measure: TC Time: twelve weeksDescription: non-HDL-cholesterol, in mg/dL
Measure: NHDL Time: twelve weeksDescription: HDL-cholesterol, in mg/dL
Measure: HDL Time: twelve weeksDescription: serum triglyceride, in mg/dL
Measure: TG Time: twelve weeksDescription: glycated hemoglobin (HbA1C), in %
Measure: HbA1C Time: twelve weeksDescription: fasting glucose, in mg/dL
Measure: FG Time: twelve weeksDescription: serum insulin, in UI/mL
Measure: Insulin Time: twelve weeksDescription: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), calculated according to fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5
Measure: HOMA-IR Time: twelve weeksDescription: CRP-us, in mg/dL; IL-6, in mg/dL; IL-10, in mg/dL
Measure: inflammatory profile Time: twelve weeksDescription: body weight, in kg;
Measure: BW Time: twelve weeksDescription: body mass index (BMI), in kg/m2, calculated according to weight (kg)/height*height (m)
Measure: BMI Time: twelve weeksDescription: waist circumference, in cm
Measure: WC Time: twelve weeksDescription: plasma fatty acids, in percentage
Measure: PFA Time: twelve weeksDescription: plasma monocytes, in percentage
Measure: Mon Time: twelve weeks